OTCMKTS:DGNOF DIAGNOS (DGNOF) Stock Price, News & Analysis $0.18 +0.00 (+2.46%) As of 05/14/2025 02:54 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesShort InterestBuy This Stock About DIAGNOS Stock (OTCMKTS:DGNOF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DIAGNOS alerts:Sign Up Key Stats Today's Range$0.17▼$0.1850-Day Range$0.17▼$0.2252-Week Range$0.17▼$0.31Volume38,000 shsAverage Volume65,892 shsMarket Capitalization$17.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewDIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.Read More… Receive DGNOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DIAGNOS and its competitors with MarketBeat's FREE daily newsletter. Email Address DGNOF Stock News HeadlinesDIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System applicationApril 16, 2025 | globenewswire.comDIAGNOS Provides Additional Information on Amendment to Convertible DebenturesApril 14, 2025 | globenewswire.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. May 15, 2025 | Altimetry (Ad)DIAGNOS Provides Update on its Health Canada Medical Device Licence ApplicationApril 9, 2025 | globenewswire.comDIAGNOS Announces Amendment to Convertible DebenturesMarch 31, 2025 | globenewswire.comDIAGNOS is filing for the Saudi FDA Authorization of Its CARA SYSTEM, an AI Assisted Medical DeviceMarch 12, 2025 | globenewswire.comDIAGNOS Announces Amendment to Convertible DebenturesFebruary 28, 2025 | globenewswire.comDIAGNOS to File for FDA Pre-Market Authorization of Its AI-Powered CARA SYSTEM and Engages Ora as Regulatory SpecialistFebruary 25, 2025 | globenewswire.comSee More Headlines DGNOF Stock Analysis - Frequently Asked Questions How have DGNOF shares performed this year? DIAGNOS's stock was trading at $0.1950 on January 1st, 2025. Since then, DGNOF shares have decreased by 10.3% and is now trading at $0.1750. View the best growth stocks for 2025 here. How were DIAGNOS's earnings last quarter? DIAGNOS Inc. (OTCMKTS:DGNOF) released its quarterly earnings data on Wednesday, February, 12th. The company reported ($0.01) EPS for the quarter. How do I buy shares of DIAGNOS? Shares of DGNOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/12/2025Today5/15/2025Next Earnings (Estimated)7/15/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorBusiness Services Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:DGNOF CIKN/A Webwww.diagnos.ca Phone(450) 678-8882FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,310,000.00 Net Margins-2,912.77% Pretax Margin-2,423.01% Return on EquityN/A Return on Assets-242.73% Debt Debt-to-Equity RatioN/A Current Ratio1.09 Quick Ratio1.09 Sales & Book Value Annual Sales$130,000.00 Price / Sales137.12 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-5.83Miscellaneous Outstanding Shares101,863,000Free FloatN/AMarket Cap$17.83 million OptionableNot Optionable Beta0.28 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (OTCMKTS:DGNOF) was last updated on 5/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DIAGNOS Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DIAGNOS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.